PNNL

Abstract

Alpha-emitting radionuclides provide effective cell-killing properties and have been shown to be effective in cancer treatment. The number of different alpha emitters having suitable physical and chemical characteristics for applications in medicine is relatively few. Development and testing of new radiopharmaceuticals requires a reliable supply of alpha-emitters in high quality, with timely delivery, but at reasonable cost. Applications and commercial availability of the follow alpha emitters are reviewed: Actinium-225, bismuth-213, astatine-211, radium-223, bismuth-212, radium-224, radium-226, terbium-149, and thorium-227. Recommendations for improving the supply of these alpha emitters include an increased federal commitment (through funding and joint-agency cooperation), establishing new production capabilities, and strengthening federal-private partnerships with companies involved in helping to meet critical radionuclide supplies.